Innovent Biologics Joins HSI and Two Other Key Indices

Written by Emily J. Thompson, Senior Investment Analyst

Updated: Nov 30 2025

0mins

Innovent Biologics Joins Hang Seng Index: Innovent Biologics has been added to the Hang Seng Index (HSI) as part of the Q3 2025 quarterly review, marking a significant achievement for the company.
First Biotech to Achieve This Milestone: This inclusion makes Innovent the first company to transition from a biotech to a leading biopharma and be recognized in the HSI, highlighting its growth and success in the industry.
Additional Index Admissions: Alongside its HSI inclusion, Innovent has also been admitted to the Hang Seng China Enterprises Index (HSCEI) and the Hang Seng ESG Enhanced Index, further solidifying its market presence.
Significance for Hong Kong's Core Assets: The addition of Innovent to these indices underscores its role as a representative of Hong Kong's core assets and the growing importance of biopharma in the region.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.